None listed
Conditions
Interventions
Intervention1: I Glow Sachet: Dosage form: Sachet
Dose:30 ml
Duration: twice a day for 90 days.
preferable 15 minutes after lunch and dinner daily.
Control Intervention1: Placebo Sachet: Dosage for
Sponsors
IndusViva HealthSciences Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects in generally good health 2. Subjects age group 18 - 55 years 3. Subjects willing to follow the suggested diet plan. 4. Subjects willing to give a written informed consent and come for a regular follow up 5. Subject willing to abide by and comply with the study protocol 6. Subject has not participated in a similar investigation in the past four weeks. 7. Subjects having visible fine lines and wrinkles in periorbital area (Crowââ?¬•s feet), nasolabial areas, forehead , and perioral regions of the face 8. Subjects having mild to moderate naso-labial folds 9. Subjects having apparent mild to moderate crowââ?¬•s feet in unanimated face 10. Subjects who have not under gone any facial anti-ageing procedures (e.g.Botulinum dermal filler injections, laser resurfacing) in the past 3 months. 11. Subject should be willing to abstain from spa treatments/facials during the study period
Exclusion criteria
Exclusion criteria: 1. A known history or present condition of allergic response to any cosmetic products. 2. Subjects having severe photo-aging. 3. Subject having skin diseases (e.g. moderate to severe acne vulgaris face or nodulocystic acne, psoriasis, active atopic dermatitis, melasma, lichen planus pigmentosus/ Achy dermatosis, pigmented contact dermatitis or other cutaneous manifestations), which will interfere with the test readings. 4. Subjects on oral medications (e.g. steroids, anti-oxidant) or any skin supplement for skin care which will compromise the study. 5. Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy. 6. Subjects not willing to discontinue other topical anti-ageing, anti- wrinkle facial products. 7. Subjects who are pregnant, lactating or nursing. 8. Hypersensitivity to any component of the tested products. 9. History of intense sun exposure. 10. Chronic illness which may influence the cutaneous state. 11. Subject participating in any other cosmetic or therapeutic trial. 12. Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Primary Measurement will be the safety and tolerability of iGlow through, a. Measuring vitals b. Laboratory Parameters Hematology, Biochemistry, liver profile, Kidney profile, Lipid Profile, Urine analysis, FBS & ECG at Screening (- 7 day) and end of the Study (90 day). Timepoint: Day 0 Day 45 and Day 90 | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. Secondary Measurement will be to assess the efficacy of iGlow through, ââ?¬Â¢ Dermatologistââ?¬â?¢s visual assessment.ii. Instrumental measurements- Visioscan (Skin topography), ââ?¬Â¢ Cutometer (Elasticity), Corneometer (Skin Hydration) & ââ?¬Â¢ Chromameter (Skin lighting). ââ?¬Â¢ iii. Subjectââ?¬â?¢s self-assessment. ââ?¬Â¢ iv. Biomarker measurement ââ?¬Â¢ a. Procollagen ââ?¬Â¢ b. Serum Collagen levels ââ?¬Â¢ c. Elastin ââ?¬Â¢ d. HAS-1 (Hyaluronic Acid Synthase-1) ââ?¬Â¢ e. CoQ10 ââ?¬Â¢ f. TEWL ((Transepidermal water loss) ââ?¬Â¢ g. Skin elasticity Timepoint: Day 0 Day 45 and Day 90 | — |
Countries
India
Contacts
Public ContactMrShariq Afsar Thandu
Radiant Research Services Pvt. Ltd
Outcome results
None listed